A Controlled Study to Assess the Efficacy, Safety and Tolerability of Oral DFD-29 Extended Release Capsules
Status:
Completed
Trial end date:
2019-03-31
Target enrollment:
Participant gender:
Summary
Clinical assessments of efficacy will be conducted based on Investigator's Global Assessment
(IGA, modified scale without erythema), Clinician's Erythema Assessment (CEA), and on
inflammatory lesion counts at Weeks 4, 8, 12 and 16 in comparison to Baseline.